To conclude, our study revealed a novel mechanism by which PAXIP1‐AS1/ETS1/WIPF1/RhoA axis regulated the development of PAH, helping better understanding the pathology of PAH and further validating PAXIP1‐AS1 as a therapeutic target for PAH treatment. This evidence concerns the gene PAXIP1 and pulmonary arterial hypertension.